Abstract
The present study evaluated the prevalence of the metabolic syndrome (MS) in a representative sample (no.=2860) of adults from the Spanish region of Galicia using the definitions of a) the World Health Organization; b) the Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults; c) the European Group for Study of Insulin Resistance; and d) the International Diabetes Federation. In addition, we assess concordance among the different definitions, and the relationships of MS with insulin resistance (IR) as assessed by the homeostatic model assessment (HOMA-IR) index. Our results indicate a high prevalence of MS under all 4 definitions. MS prevalence was higher in men than women on all 4 definitions, and increased significantly with body mass index and age. IR was high among subjects with MS, and the HOMA index was a good discriminator of MS and non-MS on all 4 definitions, suggesting that HOMA index may be a useful predictive tool in clinical practice.
Similar content being viewed by others
References
Kylin E. Studien über das Hypertonie-hyperglykemie-hyperurikemie syndrom. Zentralblatt fuer Innere Med 1923, 44: 105–27.
Vague J. Sexual differentiation, a factor affecting the forms of obesity. Presse Med 1947, 55: 339–40.
Avogaro P, Crepaldi G, Enzi G, Tiengo A. Associazione di iperlipidemia, diabete mellito e obesità di medio grado. Acta Diabetol Lat 1967, 4: 36–41.
Reaven GM. Banting Lecture 1998. Role of insulin resistance in human disease. Diabetes 1988, 37: 1595–607.
Reaven GM. Insulin resistance/compensatory hyperinsulinemia, essential hypertension, and cardiovascular disease. J Clin Endocrinol Metab 2003, 88: 2399–403.
Haffner SM, Valdez RA, Hazuda HP. Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes 1992, 41: 715–22.
Meigs JB. Invited commentary: Insulin resistance syndrome? Syndrome X? Multiple metabolic syndrome? A syndrome at all? Factor analysis reveals patterns in the fabric of correlated metabolic risk factors. Am J Epidemiol 2000, 152: 908–11.
Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005, 365: 1415–28.
Bray GA, Bellanger T. Epidemiology, trends, and morbidities of obesity and the metabolic syndrome. Endocrine 2006, 29: 109–17.
Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001, 24: 683–9.
Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005, 28: 2289–304.
Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001, 414: 782–7.
World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of the diabetes mellitus. Geneva, Switzerland, 1999.
Hills SA, Balkau B, Coppack SW, et al; EGIR-RISC Study Group. The EGIR-RISC STUDY (The European Group for the Study of Insulin Resistance: Relationship between Insulin Sensitivity and Cardiovascular Disease Risk): I. Methodology and Objectives. Diabetologia 2004, 47: 566–70.
Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112: 2735–52.
Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome: a new world-wide definition. Lancet 2005, 366: 1059–62.
Salas A, Comas D, Lareu MV, Bertranpetit J, Carracedo A. mtDNA analysis of the Galician population: a genetic edge of European variation. Eur J Hum Genet 1998, 6: 365–75.
World Health Organization. Obesity — preventing and managing the global epidemic: report of a WHO consultation on obesity. Geneva, Switzerland, 1998.
Foz M, Barbany M, Remesar X. Consenso SEEDO’2000 para la evaluación del sobrepeso y la obesidad y el establecimiento de criterios de intervención terapéutica. Sociedad Española para el estudio de la Obesidad (SEEDO). Med Clin (Barc) 2000, 115: 587–97.
Botana MA, Mato JA, Cadarso C, et al. Overweight, obesity and central obesity prevalences in the region of Galicia in Northwest Spain. Obes Metab 2007, 3: 106–15.
Perez-Fernandez R, Mariño AF, Cadarso C, et al. Prevalence, awareness, treatment and control of hypertension in Galicia (Spain) and association with related diseases. J Hum Hypertens 2007, 21: 366–73.
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2003, 26 (Suppl 1): s5–20.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis Model Assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28: 412–9.
Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome: prevalence in worldwide populations. Endocrinol Metab Clin North Am 2004, 33: 351–75.
Batsis JA, Nieto-Martinez RE, Lopez-Jimenez F. Metabolic syndrome: from global epidemiology to individualizad medicine. Clin Pharmacol Ther 2007, 8: 509–24.
Boronat M, Chirino R, Varillas VF, et al. Prevalence of metabolic syndrome in the island of Gran Canaria: comparison of three major diagnostic proposals. Diabet Med 2005, 22: 1751–6.
Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999, 16: 442–3.
Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examiation Survey. JAMA 2002, 287: 356–9.
Onat A, Ceyhan K, Basar O, et al. Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels- a prospective and cross-sectional evaluation. Atherosclerosis 2002, 165: 285–92.
Azizi F, Salehi P, Etemadi A, Zahedi-Asl S. Prevalence of metabolic syndrome in an urban population: Tehran Lipid and Glucose Study. Diabetes Res Clin Pract 2003, 61: 29–37.
Gupta A, Gupta R, Sarna M, Rastogi S, Gupta VP, Kothari K. Prevalence of diabetes impairing fasting glucose and insulin resistance syndrome in an urban Indian population. Diabetes Res Clin Pract 2003, 61: 69–76.
Athyros VG, Bouloukos VI, Pehlivanidis AN, et al; MetS-Greece Collaborative Group. The prevalence of the metabolic syndrome in Greece. The MetS-Greece Multicentre Study. Diabetes Obes Metab 2005, 7: 397–405.
Liu J, Hanley AJ, Young TK, et al. Characteristics and prevalence of the metabolic syndrome among three ethnic groups in Canada. Int J Obes (Lond) 2005, 30: 669–76.
Lorenzo C, Serrano-Rios M, Martinez-Larrad MT, et al. Central adiposity determines prevalence differences of the metabolic syndrome. Obes Res 2003, 11: 1480–7.
Bosello O, Zamboni M. Visceral obesity and metabolic syndrome. Obes Rev 2000, 1: 47–56.
Mori Y, Hoshino K, Yokota K, et al. Differences in the pathology of the metabolic syndrome with or without visceral fat accumulation. Endocrine 2006, 29: 149–53.
Zarich SW. Cardiovascular risk factors in the metabolic syndrome: impact of insulin resistance on lipids, hypertension and the development of diabetes and cardiac events. Rev Cardiovasc Med 2005, 6: 194–205.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tomé Martínez de Rituerto, M.A., Botana, M.A., Cadarso-Suárez, C. et al. Prevalence of metabolic syndrome in Galicia (NW Spain) on four alternative definitions and association with insulin resistance. J Endocrinol Invest 32, 505–511 (2009). https://doi.org/10.1007/BF03346497
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03346497